LIVIVO - Search results -

Search results

Result 1 - 10 of total 15

Search options

Article ; Online: Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between.

Han, Hyo Sook / Vikas, Praveen / Costa, Ricardo L B / Jahan, Nusrat / Taye, Ammanuel / Stringer-Reasor, Erica M

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

2023 Volume 43, Page(s) e390464

Abstract: Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or ... ...

Abstract	Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy. More recently, immunotherapy is approved to treat TNBC, but managing immune-rated adverse events while balancing efficacy is a challenge. The purpose of this review is to highlight the current treatment recommendations for early-stage TNBC and the management of immunotherapy toxicities.
MeSH term(s)	Humans ; Triple Negative Breast Neoplasms/drug therapy ; Immunotherapy
Language	English
Publishing date	2023-06-19
Publishing country	United States
Document type	Review ; Journal Article
ZDB-ID	2431126-1
ISSN	1548-8756 ; 1548-8748
ISSN (online)	1548-8756
ISSN	1548-8748
DOI	10.1200/EDBK_390464
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.

Layman, Rachel M / Han, Hyo S / Rugo, Hope S / Stringer-Reasor, Erica M / Specht, Jennifer M / Dees, E Claire / Kabos, Peter / Suzuki, Samuel / Mutka, Sarah C / Sullivan, Brian F / Gorbatchevsky, Igor / Wesolowski, Robert

The Lancet. Oncology

2024 Volume 25, Issue 4, Page(s) 474–487

Abstract: Background: The PI3K-mTOR pathway is frequently dysregulated in breast cancer. Combining an inhibitor targeting all class I PI3K isoforms and mTOR complex 1 (mTORC1)-mTOR complex 2 (mTORC2) with endocrine therapy and a CDK4/6 inhibitor might provide ... ...

Abstract	Background: The PI3K-mTOR pathway is frequently dysregulated in breast cancer. Combining an inhibitor targeting all class I PI3K isoforms and mTOR complex 1 (mTORC1)-mTOR complex 2 (mTORC2) with endocrine therapy and a CDK4/6 inhibitor might provide more effective tumour control than standard-of-care therapy. To evaluate this hypothesis, gedatolisib, a pan-PI3K-mTOR inhibitor, was assessed in a phase 1b trial combined with palbociclib and endocrine therapy in patients with hormone receptor-positive, HER2-negative, advanced breast cancer. Results from the dose expansion portion of this trial are reported herein. Methods: This multicentre, open-label, phase 1b study recruited female patients aged at least 18 years from 17 sites across the USA with hormone-receptor-positive, HER2-negative, advanced breast cancer and an Eastern Cooperative Oncology Group performance status of 0-1. Four patient groups were studied in the dose expansion portion of the study: treatment-naive in the advanced setting (first line; group A), progression on 1-2 lines of endocrine therapy but CDK4/6 inhibitor-naive (group B); and one or more previous lines (second-line and higher) of therapy, including a CDK4/6 inhibitor (groups C and D). Gedatolisib 180 mg was administered intravenously weekly in 28-day treatment cycles for groups A-C, and on days 1, 8, and 15 for group D. Letrozole (group A), fulvestrant (groups B-D), and palbociclib (all groups) were administered at standard doses and schedules. The primary endpoint was investigator-assessed objective response rate per RECIST version 1.1 in the evaluable analysis set. This trial is completed and registered with ClinicalTrials.gov, NCT02684032. Findings: Between Dec 19, 2017, and June 19, 2019, 103 female participants were enrolled in the dose expansion groups A (n=31), B (n=13), C (n=32), and D (n=27). Median follow-up was 16·6 months (IQR 5·7-48·4) for group A, 11·0 months (7·6-16·9) for group B, 3·6 months (1·8-7·5) for group C, and 9·4 months (5·3-16·7) for group D for the primary endpoint. Gedatolisib, palbociclib, and endocrine therapy induced an objective response in 23 (85·2%; 90% CI 69·2-94·8) of 27 evaluable first-line participants (group A). In the second-line and higher setting, an objective response was observed in eight (61·5%; 90% CI 35·5-83·4) of 13 evaluable group B participants, seven (25·0%; 12·4-41·9) of 28 evaluable group C participants, and 15 (55·6%; 38·2-72·0) of 27 evaluable group D participants; this included participants with both wild-type and mutated PIK3CA tumours. The most common grade 3-4 treatment-related adverse events were neutropenia (65 [63%] of 103), stomatitis (28 [27%]), and rash (21 [20%]). Grade 3-4 hyperglycaemia was reported in six (6%) participants. 23 (22%) of 103 participants had a treatment-related serious adverse event, and there were no treatment-related deaths. Nine (9%) participants discontinued treatment because of a treatment-emergent adverse event. Interpretation: Gedatolisib plus palbociclib and endocrine therapy showed a promising objective response rate compared with the published results for standard-of-care therapies and had an acceptable safety profile. Funding: Pfizer and Celcuity.
MeSH term(s)	Female ; Humans ; Adolescent ; Adult ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Receptor, ErbB-2/metabolism ; Disease-Free Survival ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; TOR Serine-Threonine Kinases ; Morpholines ; Piperazines ; Pyridines ; Triazines
Chemical Substances	palbociclib (G9ZF61LE7G) ; gedatolisib (96265TNH2R) ; Receptor, ErbB-2 (EC 2.7.10.1) ; TOR Serine-Threonine Kinases (EC 2.7.11.1) ; Morpholines ; Piperazines ; Pyridines ; Triazines
Language	English
Publishing date	2024-03-26
Publishing country	England
Document type	Multicenter Study ; Clinical Trial, Phase I ; Journal Article
ZDB-ID	2049730-1
ISSN	1474-5488 ; 1470-2045
ISSN (online)	1474-5488
ISSN	1470-2045
DOI	10.1016/S1470-2045(24)00034-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5696: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 460: Show issues

Order via subito

Details ▾

Article ; Online: Disparities in Breast Cancer Associated With African American Identity.

Stringer-Reasor, Erica M / Elkhanany, Ahmed / Khoury, Katia / Simon, Melissa A / Newman, Lisa A

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

2021 Volume 41, Page(s) e29–e46

Abstract: Persistent disparities in the burden of breast cancer between African Americans and White Americans have been documented over many decades. Features characterizing breast cancer in the African American community include a 40% higher mortality rate, ... ...

Abstract	Persistent disparities in the burden of breast cancer between African Americans and White Americans have been documented over many decades. Features characterizing breast cancer in the African American community include a 40% higher mortality rate, younger age distribution, greater advanced-stage distribution, increased risk of biologically aggressive disease such as the triple-negative phenotype, and increased incidence of male breast cancer. Public health experts, genetics researchers, clinical trialists, multidisciplinary oncology teams, and advocates must collaborate to comprehensively address the multifactorial etiology of and remedies for breast cancer disparities. Efforts to achieve breast health equity through improved access to affordable, high-quality care are especially imperative in the context of the COVID-19 pandemic and its disproportionately high economic toll on African Americans.
MeSH term(s)	African Americans/psychology ; Breast Neoplasms/epidemiology ; Breast Neoplasms/pathology ; COVID-19/epidemiology ; COVID-19/pathology ; European Continental Ancestry Group/psychology ; Female ; Healthcare Disparities/trends ; Humans ; Pandemics ; SARS-CoV-2/pathogenicity ; Socioeconomic Factors
Language	English
Publishing date	2021-06-23
Publishing country	United States
Document type	Journal Article
ZDB-ID	2431126-1
ISSN	1548-8756 ; 1548-8748
ISSN (online)	1548-8756
ISSN	1548-8748
DOI	10.1200/EDBK_319929
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.

Vaklavas, Christos / Stringer-Reasor, Erica M / Elkhanany, Ahmed M / Ryan, Kevin J / Li, Yufeng / Theuer, Charles P / Acosta, Edward P / Wei, Shi / Yang, Eddy S / Grizzle, William E / Forero-Torres, Andres

Breast cancer research and treatment

2023 Volume 198, Issue 2, Page(s) 217–229

Abstract: Purpose: In nonmetastatic hormone receptor-positive and Her2-negative breast cancer, preoperative endocrine therapies can yield outcomes similar with chemotherapy. We evaluated the tolerability and preliminary antitumor activity of preoperative ... ...

Abstract	Purpose: In nonmetastatic hormone receptor-positive and Her2-negative breast cancer, preoperative endocrine therapies can yield outcomes similar with chemotherapy. We evaluated the tolerability and preliminary antitumor activity of preoperative letrozole, everolimus, and carotuximab, a monoclonal antibody targeting endoglin, in nonmetastatic breast cancer. Methods: Eligible patients had newly diagnosed, stage 2 or 3, hormone receptor-positive and Her2/neu-negative breast cancer. Patients received escalating doses of everolimus; the dose of letrozole and carotuximab were fixed at 2.5 mg PO daily and 15 mg/kg intravenously every 2 weeks, respectively. The primary objective was to determine the safety and tolerability of the combination. Secondary objectives included pharmacokinetic and pharmacodynamic studies and assessments of antitumor activity. Results: Fifteen patients enrolled. The recommended phase 2 dose of everolimus in combination with letrozole and carotuximab was 10 mg PO daily. The most frequent adverse events were headache (67%), fatigue (47%), facial flushing and swelling (47%), gingival hemorrhage (40%), epistaxis (33%), nausea and vomiting (27%). Headache constituted a dose-limiting toxicity. At least two signs of mucocutaneous telangiectasia developed in 92% of patients. Carotuximab accumulated in the extravascular space and accelerated the biodistribution and clearance of everolimus. All patients had residual disease. Gene expression analyses were consistent with downregulation of genes involved in proliferation and DNA repair. Among 6 patients with luminal B breast cancer, 5 converted to luminal A after one cycle of therapy. Conclusion: Letrozole, everolimus, and carotuximab were tolerated in combination at their single-agent doses. Pharmacokinetic studies revealed an interaction between everolimus and carotuximab. Trial registration: This trial is registered with ClinicalTrials.gov (Identifier: NCT02520063), first posted on August 11, 2015, and is active, not recruiting.
MeSH term(s)	Humans ; Female ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Letrozole ; Everolimus ; Tissue Distribution ; Receptor, ErbB-2/metabolism ; Biomarkers, Tumor/genetics ; Antibodies, Monoclonal/metabolism ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Chemical Substances	Letrozole (7LKK855W8I) ; Everolimus (9HW64Q8G6G) ; carotuximab (YB2EWE6139) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Biomarkers, Tumor ; Antibodies, Monoclonal
Language	English
Publishing date	2023-02-03
Publishing country	Netherlands
Document type	Clinical Trial, Phase II ; Clinical Trial, Phase I ; Journal Article
ZDB-ID	604563-7
ISSN	1573-7217 ; 0167-6806
ISSN (online)	1573-7217
ISSN	0167-6806
DOI	10.1007/s10549-023-06864-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1655: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Lynce, Filipa / Mainor, Candace / Donahue, Renee N / Geng, Xue / Jones, Greg / Schlam, Ilana / Wang, Hongkun / Toney, Nicole J / Jochems, Caroline / Schlom, Jeffrey / Zeck, Jay / Gallagher, Christopher / Nanda, Rita / Graham, Deena / Stringer-Reasor, Erica M / Denduluri, Neelima / Collins, Julie / Chitalia, Ami / Tiwari, Shruti /

Nunes, Raquel / Kaltman, Rebecca / Khoury, Katia / Gatti-Mays, Margaret / Tarantino, Paolo / Tolaney, Sara M / Swain, Sandra M / Pohlmann, Paula / Parsons, Heather A / Isaacs, Claudine

Nature communications

2024 Volume 15, Issue 1, Page(s) 3957

Language	English
Publishing date	2024-05-10
Publishing country	England
Document type	Published Erratum
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-024-48359-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Nunes, Raquel / Kaltman, Rebecca / Khoury, Katia / Gatti-Mays, Margaret / Tarantino, Paolo / Tolaney, Sara M / Swain, Sandra M / Pohlmann, Paula / Parsons, Heather A / Isaacs, Claudine

Nature communications

2024 Volume 15, Issue 1, Page(s) 2691

Abstract: Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing ... ...

Abstract	Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints included the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes. Forty-five women with TNBC and residual invasive disease after standard neoadjuvant chemotherapy were randomized to nivolumab, capecitabine, or the combination. Here we show that a combination of nivolumab plus capecitabine leads to a greater increase in PIS from baseline to week 6 (91%) compared with nivolumab (47%) or capecitabine (53%) alone (log-rank p = 0.08), meeting the pre-specified primary endpoint. In addition, the presence of circulating tumor DNA (ctDNA) is associated with disease recurrence, with no new safety signals in the combination arm. Our results provide efficacy and safety data on this combination in TNBC and support further development of PIS and ctDNA analyses to identify patients at high risk of recurrence.
MeSH term(s)	Humans ; Female ; Capecitabine/adverse effects ; Nivolumab/therapeutic use ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/pathology ; Neoplasm Recurrence, Local/pathology ; Neoadjuvant Therapy ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Chemical Substances	Capecitabine (6804DJ8Z9U) ; Nivolumab (31YO63LBSN)
Language	English
Publishing date	2024-03-27
Publishing country	England
Document type	Randomized Controlled Trial ; Clinical Trial, Phase II ; Journal Article
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-024-46961-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.

Stringer-Reasor, Erica M / May, Jori E / Olariu, Eva / Caterinicchia, Valerie / Li, Yufeng / Chen, Dongquan / Della Manna, Deborah L / Rocque, Gabrielle B / Vaklavas, Christos / Falkson, Carla I / Nabell, Lisle M / Acosta, Edward P / Forero-Torres, Andres / Yang, Eddy S

Breast cancer research : BCR

2021 Volume 23, Issue 1, Page(s) 30

Abstract: Background: Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple- ... ...

Abstract	Background: Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA repair, we have previously shown an induced synthetic lethality with combined EGFR inhibition and PARPi. Here, we report the safety and clinical activity of lapatinib and veliparib in patients with metastatic TNBC. Methods: A first-in-human, pilot study of lapatinib and veliparib was conducted in metastatic TNBC (NCT02158507). The primary endpoint was safety and tolerability. Secondary endpoints were objective response rates and pharmacokinetic evaluation. Gene expression analysis of pre-treatment tumor biopsies was performed. Key eligibility included TNBC patients with measurable disease and prior anthracycline-based and taxane chemotherapy. Patients with gBRCA1/2 mutations were excluded. Results: Twenty patients were enrolled, of which 17 were evaluable for response. The median number of prior therapies in the metastatic setting was 1 (range 0-2). Fifty percent of patients were Caucasian, 45% African-American, and 5% Hispanic. Of evaluable patients, 4 demonstrated a partial response and 2 had stable disease. There were no dose-limiting toxicities. Most AEs were limited to grade 1 or 2 and no drug-drug interactions noted. Exploratory gene expression analysis suggested baseline DNA repair pathway score was lower and baseline immunogenicity was higher in the responders compared to non-responders. Conclusions: Lapatinib plus veliparib therapy has a manageable safety profile and promising antitumor activity in advanced TNBC. Further investigation of dual therapy with EGFR inhibition and PARP inhibition is needed. Trial registration: ClinicalTrials.gov , NCT02158507 . Registered on 12 September 2014.
MeSH term(s)	Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Benzimidazoles/administration & dosage ; Benzimidazoles/pharmacokinetics ; Disease Management ; Drug Monitoring ; Female ; Humans ; Lapatinib/administration & dosage ; Lapatinib/pharmacokinetics ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Pilot Projects ; Treatment Outcome ; Triple Negative Breast Neoplasms/diagnostic imaging ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/pathology
Chemical Substances	Benzimidazoles ; veliparib (01O4K0631N) ; Lapatinib (0VUA21238F)
Language	English
Publishing date	2021-03-04
Publishing country	England
Document type	Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2015059-3
ISSN	1465-542X ; 1465-5411
ISSN (online)	1465-542X
ISSN	1465-5411
DOI	10.1186/s13058-021-01408-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5494: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Nunes, Raquel / Kaltman, Rebecca / Khoury, Katia / Gatti-Mays, Margaret / Tarantino, Paolo / Tolaney, Sara M / Swain, Sandra M / Pohlmann, Paula / Parsons, Heather A / Isaacs, Claudine

medRxiv : the preprint server for health sciences

2023

Abstract	Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints include the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes. Forty-five women with TNBC and residual invasive disease after standard neoadjuvant chemotherapy were randomized to nivolumab, capecitabine, or the combination. Here we show that a combination of nivolumab plus capecitabine leads to a greater increase in PIS from baseline to week 6 (91%) compared with nivolumab (47%) or capecitabine (53%) alone (log-rank p = 0.08), meeting the pre-specified primary endpoint. In addition, the presence of circulating tumor DNA (ctDNA) was associated with disease recurrence, with no new safety signals in the combination arm. Our results provide efficacy and safety data on this combination in TNBC and support further development of PIS and ctDNA analyses to identify patients at high risk of recurrence.
Language	English
Publishing date	2023-12-04
Publishing country	United States
Document type	Preprint
DOI	10.1101/2023.12.04.23297559
Database	MEDical Literature Analysis and Retrieval System OnLINE

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.

Stringer-Reasor, Erica M / Baker, Gabrielle M / Skor, Maxwell N / Kocherginsky, Masha / Lengyel, Ernst / Fleming, Gini F / Conzen, Suzanne D

Gynecologic oncology

2015 Volume 138, Issue 3, Page(s) 656–662

Abstract: Objectives: To test the hypothesis that glucocorticoid receptor (GR) activation increases resistance to chemotherapy in high-grade serous ovarian cancer (HGS-OvCa) and that treatment with a GR antagonist will improve sensitivity to chemotherapy.: ... ...

Abstract	Objectives: To test the hypothesis that glucocorticoid receptor (GR) activation increases resistance to chemotherapy in high-grade serous ovarian cancer (HGS-OvCa) and that treatment with a GR antagonist will improve sensitivity to chemotherapy. Methods: GR expression was assessed in OvCa cell lines by qRT-PCR and Western blot analysis and in xenografts and primary human tumors using immunohistochemistry (IHC). We also examined the effect of GR activation versus inhibition on chemotherapy-induced cytotoxicity in OvCa cell lines and in a xenograft model. Results: With the exception of IGROV-1 cells, all OvCa cell lines tested had detectable GR expression by Western blot and qRT-PCR analysis. Twenty-five out of the 27 human primary HGS-OvCas examined expressed GR by IHC. No cell line expressed detectable progesterone receptor (PR) or androgen receptor (AR) by Western blot analysis. In vitro assays showed that in GR-positive HeyA8 and SKOV3 cells, dexamethasone (100nM) treatment upregulated the pro-survival genes SGK1 and MKP1/DUSP1 and inhibited carboplatin/gemcitabine-induced cell death. Concurrent treatment with two GR antagonists, either mifepristone (100nM) or CORT125134 (100nM), partially reversed these effects. There was no anti-apoptotic effect of dexamethasone on chemotherapy-induced cell death in IGROV-1 cells, which did not have detectable GR protein. Mifepristone treatment alone was not cytotoxic in any cell line. HeyA8 OvCa xenograft studies demonstrated that adding mifepristone to carboplatin/gemcitabine increased tumor shrinkage by 48% compared to carboplatin/gemcitabine treatment alone (P=0.0004). Conclusions: These results suggest that GR antagonism sensitizes GR+ OvCa to chemotherapy-induced cell death through inhibition of GR-mediated cell survival pathways.
MeSH term(s)	Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Carcinoma, Ovarian Epithelial ; Cell Death/drug effects ; Cell Line, Tumor ; Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/metabolism ; Cystadenocarcinoma, Serous/pathology ; Drug Resistance, Neoplasm ; Female ; Humans ; Immunohistochemistry ; MCF-7 Cells ; Mice ; Mice, SCID ; Mifepristone/pharmacology ; Neoplasms, Glandular and Epithelial/drug therapy ; Neoplasms, Glandular and Epithelial/metabolism ; Neoplasms, Glandular and Epithelial/pathology ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Random Allocation ; Receptors, Glucocorticoid/antagonists & inhibitors ; Receptors, Glucocorticoid/metabolism ; Xenograft Model Antitumor Assays
Chemical Substances	Receptors, Glucocorticoid ; Mifepristone (320T6RNW1F)
Language	English
Publishing date	2015-06-24
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	801461-9
ISSN	1095-6859 ; 0090-8258
ISSN (online)	1095-6859
ISSN	0090-8258
DOI	10.1016/j.ygyno.2015.06.033
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 885: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.

Gradishar, William J / Moran, Meena S / Abraham, Jame / Abramson, Vandana / Aft, Rebecca / Agnese, Doreen / Allison, Kimberly H / Anderson, Bethany / Burstein, Harold J / Chew, Helen / Dang, Chau / Elias, Anthony D / Giordano, Sharon H / Goetz, Matthew P / Goldstein, Lori J / Hurvitz, Sara A / Jankowitz, Rachel C / Javid, Sara H / Krishnamurthy, Jairam /

Leitch, A Marilyn / Lyons, Janice / Mortimer, Joanne / Patel, Sameer A / Pierce, Lori J / Rosenberger, Laura H / Rugo, Hope S / Schneider, Bryan / Smith, Mary Lou / Soliman, Hatem / Stringer-Reasor, Erica M / Telli, Melinda L / Wei, Mei / Wisinski, Kari B / Young, Jessica S / Yeung, Kay / Dwyer, Mary A / Kumar, Rashmi

Journal of the National Comprehensive Cancer Network : JNCCN

2023 Volume 21, Issue 6, Page(s) 594–608

Abstract: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly. The therapeutic strategy takes into ... ...

Abstract	The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly. The therapeutic strategy takes into consideration tumor biology, biomarkers, and other clinical factors. Due to the growing number of treatment options, if one option fails, there is usually another line of therapy available, providing meaningful improvements in survival. This NCCN Guidelines Insights report focuses on recent updates specific to systemic therapy recommendations for patients with stage IV (M1) disease.
MeSH term(s)	Humans ; Female ; Breast Neoplasms ; Medical Oncology
Language	English
Publishing date	2023-06-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	2250759-0
ISSN	1540-1413 ; 1540-1405
ISSN (online)	1540-1413
ISSN	1540-1405
DOI	10.6004/jnccn.2023.0031
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6365: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito